Adjuvant development program
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93018C00049
- Awardee
-
Virovax LLC UEI H9QWJVY8MT78
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $9,273,316
Award facts
- Opportunity
-
- HHSNIHNIAIDBAA20171 Solicitation number
- Contract value 100% obligated
- $9,273,316.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 17 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Lawrence, KS 66047, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$468 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | -$123 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $274,999 | |
| Exercise an Option | $1,983,970 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $3,385,434 | |
| Supplemental Agreement for work within scope | $249,994 | |
| Supplemental Agreement for work within scope | $649,995 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $1,216,047 | |
| Original award | $1,513,468 |
Show all 17
About this award
This is a cost-type definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virovax LLC, a minority-owned limited liability company, for an Adjuvant Development Program. The contract has a ceiling value of $9,273,316.19 and a period of performance through September 29, 2025. The contract was awarded on September 30, 2018 and does not utilize a set-aside designation. As NIAID is the funding agency, this award is likely supporting the institute's research and development efforts in the area of adjuvants, which are substances used to enhance the immune response to vaccines.
Quick answers
Who was awarded contract 75N93018C00049?
75N93018C00049 was awarded to Virovax LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2018.
How much is contract 75N93018C00049 worth?
The government has obligated $9,273,316 on 75N93018C00049.
Was contract 75N93018C00049 competed?
The extent of competition for 75N93018C00049 was full and open competition. The government received 17 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award